Jean-Luc Labourey

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

Gwénaëlle Gravis, Karim Fizazi, Florence Joly et al. · The Lancet Oncology · 2013 · 727 citations

Androgen-deprivation Therapy, Urology, Genitourinary Cancer +7

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

Karim Fizazi, Laura Faivre, F. Lesaunier et al. · The Lancet Oncology · 2015 · 236 citations

Urology, Getug 12, Genitourinary Cancer +8

Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model

Gwénaëlle Gravis, Jean‐Marie Boher, Karim Fizazi et al. · European Urology · 2014 · 128 citations · Full text

Prognostic Factors, Urology, Genitourinary Cancer +6

Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)

Gwénaëlle Gravis, Patricia Marino, Florence Joly et al. · European Journal of Cancer · 2014 · 65 citations

Urology, Meta-analysis, Medicine +11

Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study

Sandrine Lavau‐Denès, Philippe Lacroix, A. Maubon et al. · Cancer Chemotherapy and Pharmacology · 2013 · 60 citations

Thrombosis, Venous Thrombosis, Oncology +11